• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    1,031.15 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 45
    Open 1,031.15
    Bid (Size) 968.00 (8)
    Ask (Size) 1,179.00 (1)
    Prev. Close 1,031.15
    Today's Range 1,031.15 - 1,031.15
    52wk Range 769.19 - 1,211.20
    Shares Outstanding 91,779,465
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
    Via Benzinga
    Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
    Via Benzinga

    Performance

    YTD
    +13.94%
    +13.94%
    1 Month
    -14.03%
    -14.03%
    3 Month
    -3.56%
    -3.56%
    6 Month
    +6.71%
    +6.71%
    1 Year
    +23.88%
    +23.88%

    More News

    Read More
    Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
    Via Benzinga
    Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
    Via Benzinga
    This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga
    Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Smart Money Is Betting Big In REGN Options
    Via Benzinga
    Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
    Via Benzinga
    Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
    Via Investor's Business Daily
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Time To Invest And Or Trade In Bio-Tech Stocks?
    Via Talk Markets
    Topics ETFs
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
    Via Benzinga
    Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
    Via Benzinga
    Biotech Breakout: Stocks for Your Watchlist
    Via MarketBeat
    Topics ETFs
    Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
    Via Benzinga
    MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
    Via News Direct
    EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Prediction: These 2 Companies Will Split Their Stocks by 2027
    Via The Motley Fool
    Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
    Via The Motley Fool
    Biotech And Life Science Sector Update Summer Of 2024
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.